Medical Oncologist
CION Cancer Clinics
CDKN2A mutation: which cancers, and how much risk | CION Cancer Clinics
A harmful change in the CDKN2A gene mainly raises the risk of two cancers: melanoma, a cancer of the skin's pigment cells, and cancer of the pancreas. The rise is real, but it is not a certainty, and it varies a great deal between families. This page explains which cancers are linked, what pushes one person's risk up or down, and why figures from other countries may not fit an Indian family. At CION Cancer Clinics, our oncologists explain what a gene result means for you and your family, and plan the checks that follow.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Which cancers does a CDKN2A fault raise the risk of?
- How strong is the link for each cancer?
- What decides where one carrier's risk sits?
- What do the words on a CDKN2A report mean?
- What pushes the risk up, and what may help?
- What this page cannot tell you
- Four things families believe about CDKN2A, and what is true
- Common questions about CDKN2A cancer risk
The short answer
Which cancers does a CDKN2A fault raise the risk of?
Mainly two. A harmful change in CDKN2A raises the lifetime risk of melanoma, and it raises the risk of cancer of the pancreas. Both risks are substantially higher than in the general population. Neither is a certainty, and many carriers never develop either cancer.
Why one gene affects two organs
CDKN2A makes a brake that stops cells dividing when they should not. Every cell in a carrier's body starts life with one working copy of that brake instead of two. Pigment cells in the skin and the cells lining the pancreas seem to lean on this brake more heavily than most, which is why these two organs carry most of the extra risk.
Why the figures you read vary so much
Published risk figures come mostly from fair-skinned families in Australia, Europe and North America, where strong sunshine drives melanoma. They also come from families studied because many relatives were already ill, which pushes estimates up. For a family in Telangana, the melanoma figure in particular may not transfer. Studies in Indian families are very small.
A raised risk is a reason to be watched. It is not a forecast.Cancer by cancer
How strong is the link for each cancer?
The evidence is strong for the first two cards and thin for the rest.
Melanoma
The main cancer linked to CDKN2A. Carriers are more likely to develop melanoma, to develop it younger, and to have more than one separate melanoma over a lifetime. Many also have large numbers of moles, some unusual in shape or colour.
Risk rises with
- Strong sun exposure over many years
- Fair skin that burns easily
- A large number of moles
Pancreatic cancer
The second clearly linked cancer, and the reason carriers are often offered pancreatic surveillance. The risk is raised whether or not a relative has had pancreatic cancer, though a family history pushes it higher. Smoking makes it considerably worse.
Stopping tobacco is the single change with the clearest effect on this risk.Possible links, weaker evidence
Some studies suggest a modest rise in cancers of the head and neck and of the lung, mostly among carriers who smoke. A few families with larger missing pieces of the gene have had tumours of the brain and nerves. These links rest on small numbers.
Not clearly linked
Breast, bowel, ovarian and prostate cancer are not established CDKN2A cancers. If they also run in your family, a different gene may be involved. That is one reason a counsellor usually tests a panel of genes rather than one.
Not sure whether this applies to you?
Ask an oncologistYour own risk
What decides where one carrier's risk sits?
The exact change in the gene
Different faults in CDKN2A do not behave identically. Some well-studied changes in European families carry a higher pancreatic risk than others. Your report names your exact change, and a counsellor can tell you what is known about it.
Who else in the family was affected
A family with several pancreatic cancers suggests a higher risk than the gene alone would. The pattern of illness around you is part of the estimate, not a separate question.
Skin colour and sunlight
Melanoma risk depends heavily on sunlight and skin type. Carriers with darker skin appear to have a lower melanoma risk than fair-skinned carriers, although Indian data are too thin to put a figure on it.
Tobacco
Smoking raises pancreatic cancer risk in anyone. In CDKN2A carriers the effect appears stronger, and the possible rise in head, neck and lung cancer seems concentrated in smokers too.
Age
Both risks grow with age. Melanoma can appear in early adult life in carrier families, while pancreatic cancer in carriers is still more common from middle age onwards.
On your report
What do the words on a CDKN2A report mean?
- CDKN2A
- The gene's name. It holds the instructions for two brake proteins, called p16 and p14ARF, that stop damaged cells from dividing.
- Pathogenic variant
- A change in the gene known to stop it working. Likely pathogenic means the laboratory is fairly sure, but not certain.
- Heterozygous
- One copy of the gene carries the fault and the other copy is normal. This is what almost every carrier's report says.
- Penetrance
- How often a fault actually leads to cancer across everyone who carries it. For CDKN2A it differs by cancer, by family and by country.
- Atypical mole
- A mole that looks unusual, with an uneven edge, mixed colours or a larger size. It is not cancer, but it is watched closely.
- Germline
- Present in every cell from birth, and so able to pass to children. A change found only inside a tumour is a different finding.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Side by side
What pushes the risk up, and what may help?
Tends to push risk up
What may help
Smoking, beedis or chewed tobacco
Stopping all tobacco, at any age
Repeated sunburn and hours in strong sun
Shade, covering clothes and sunscreen outdoors
Many moles, some of them unusual
Regular skin checks by a skin specialist
Several relatives with pancreatic cancer
Pancreatic surveillance in an experienced centre
Heavy drinking and repeated pancreatitis
Cutting down alcohol and treating the inflammation
Being straight with you
What this page cannot tell you
It cannot give you your own number. Your risk depends on your exact variant, your family's pattern of illness, your skin and your habits, and only someone who has seen all four can estimate it honestly. What your specific variant means is a question for the counsellor who ordered the test.
It cannot read a tumour report
CDKN2A changes are very common inside tumours of many kinds. A change found only in the tumour usually says nothing about the family and is used to guide treatment. That kind of testing is covered on our targeted therapy pages, not here.
Who this does not apply to
Most people with one relative who had melanoma or pancreatic cancer do not carry a CDKN2A fault and do not need this test. A single cancer in an older relative who smoked rarely points to this gene. Testing is usually considered when a family has several melanomas, melanoma and pancreatic cancer together, or one person with more than one separate melanoma.
Commonly believed
Four things families believe about CDKN2A, and what is true
"Melanoma is a foreigner's disease, so this gene cannot matter for us."
Melanoma is less common in darker skin, but it happens, often on the soles, palms, under the nails or inside the mouth, where sunlight plays little part. The pancreatic risk from CDKN2A does not depend on skin colour at all.
"No one in our family had pancreatic cancer, so we can ignore that part."
Carriers have a raised pancreatic risk even without an affected relative. That is why current expert guidance offers pancreatic surveillance to carriers themselves, not only to those with a family history.
"A positive result means cancer is coming."
Many carriers never develop melanoma or pancreatic cancer. The result tells you where to look and how closely, which is the whole point of finding it.
"Sunscreen alone will cancel the risk."
Sun protection helps with melanoma, but it does nothing for the pancreas. Carriers need skin checks and a pancreatic plan, and giving up tobacco matters more than any cream.
Questions we are asked
Common questions about CDKN2A cancer risk
Do men and women carry the same risk?
Broadly, yes. CDKN2A is not on a sex chromosome, so a father can carry and pass it on exactly as a mother can. Any difference between men and women in a family usually reflects habits such as smoking and time spent outdoors, not the gene itself.
Can children in a carrier family get melanoma?
It is uncommon in childhood, even in carrier families, though it can occasionally appear in the teenage years. Every child in the family benefits from sun protection and from a parent noticing new or changing moles, whether or not they have been tested.
Do the risk figures online apply to my family?
Not directly. Most come from fair-skinned families abroad, many of them selected because several relatives were already ill. Your counsellor will use your own family tree and your exact variant to explain where your risk probably sits, and say plainly where the evidence runs out.
If I test negative, is my risk back to normal?
If your family's known CDKN2A fault was looked for and not found, you did not inherit it, and your risk from this gene is the same as anyone's. If no fault was ever found in the family, a negative result is less reassuring, and your family history still counts.
Should a carrier avoid the sun completely?
No. The aim is to avoid burning and long hours in strong midday sun, not to live indoors. Shade, a hat, covering clothes and sunscreen on exposed skin are enough for most people. Ask your doctor about vitamin D if you cover up heavily.
Is pancreatic surveillance worth doing?
It can find early changes in some carriers while they can still be treated, which is why expert groups recommend it. The evidence on long-term benefit is still growing. It works best in a centre that runs a proper programme, with the same team reading every scan.
Does a CDKN2A fault raise breast cancer risk?
It is not an established breast cancer gene. If breast cancer also runs in your family, that is usually a separate question, and a panel test may look at the genes more often linked to it. Your counsellor will explain which findings explain which cancers.
What should I do first after a positive result?
Book a follow-up with your genetic counsellor, arrange a full skin check with a skin specialist, and stop all tobacco if you use it. Then make a list of parents, brothers, sisters and children who could be offered the same test. Call the CION helpline if you need help arranging any of it.
Your Specialists
Meet CION's oncologists. Bring your family history or genetic report to them.
Our medical oncologists see people with a strong family history of cancer, arrange genetic counselling and testing where it fits, and plan the checks that follow.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- MedlinePlus Genetics — CDKN2A gene
- National Cancer Institute — Genetics of Skin Cancer (PDQ) – Health Professional Version
- MedlinePlus Genetics — Melanoma
- Cancer Research UK — Risks and causes of pancreatic cancer
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Talk to us
Melanoma or pancreatic cancer in more than one relative?
Tell us who in the family was diagnosed, with what, and at what age. We will tell you honestly whether a genetic referral makes sense, and arrange it if it does. One helpline serves every CION centre.